Department of Health Systems Science, College of Nursing, University of Illinois at Chicago, Rockford, Illinois.
Swedish American Medical Group, Rockford, Illinois.
J Midwifery Womens Health. 2019 May;64(3):276-288. doi: 10.1111/jmwh.12968. Epub 2019 Apr 12.
The potential role of vitamin D in the development of breast cancer has been the subject of considerable interest. Laboratory and genetic studies demonstrate promising anticarcinogenic effects of vitamin D. However, inconsistencies persist in results of human studies that have assessed vitamin D supplementation for the prevention of primary and secondary cancers. Despite these discrepancies, screening for vitamin D deficiency and vitamin D supplementation have increased dramatically in the past decade. No official institutional guidelines recommend vitamin D supplementation for cancer prevention, and yet these newly adopted practice norms have outpaced rigorous scientific study. Higher circulating levels of vitamin D [25-hydroxyvitamin D, or 25(OH)D] appear to be associated with reduced risk and improved survivorship of certain malignancies. However, the association has not been found for all cancers. This state of the science review examines the association between vitamin D supplementation, circulating 25(OH)D level, vitamin D receptor polymorphisms, and the risk and mortality of breast cancer. The review addresses the role of supplementation and optimal 25(OH)D levels.
维生素 D 对乳腺癌发展的潜在作用一直是相当关注的话题。实验室和遗传研究表明维生素 D 具有有希望的抗癌作用。然而，评估维生素 D 补充剂预防原发性和继发性癌症的人体研究结果仍然存在不一致。尽管存在这些差异，过去十年中对维生素 D 缺乏症的筛查和维生素 D 补充剂的使用显著增加。没有官方机构指南建议使用维生素 D 补充剂来预防癌症，然而这些新采用的实践规范已经超过了严格的科学研究。较高的循环维生素 D 水平[25-羟维生素 D，或 25(OH)D]似乎与某些恶性肿瘤的风险降低和生存率提高有关。然而，并非所有癌症都发现了这种关联。本科学审查研究了维生素 D 补充剂、循环 25(OH)D 水平、维生素 D 受体多态性与乳腺癌风险和死亡率之间的关系。本综述探讨了补充剂和最佳 25(OH)D 水平的作用。
